Stocktoria

Quince Therapeutics, Inc. QNCX

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2019-05-09

Quince Therapeutics, Inc. statistics & valuation

Market cap$15.4M
Net cash$5.8M
Enterprise value USD$9.6M
Return on capital-115.5%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
20182019202020212022202320242025
Operating margin (%)
20182019202020212022202320242025
Return on equity (%)
-32.00% -44.60% -75.80% -51.40% -36.90% -188.50% 20182019202020212022202320242025
Shares outstanding
3.4M 26.9M 29.5M 30.1M 36.1M 43.0M 44.0M 50.1M 20182019202020212022202320242025
Net debt ($)
-$40.6M $13.4M $8.1M -$5.8M 20182019202020212022202320242025
Share buybacks ($)
20182019202020212022202320242025
Return on assets (%)
-17.10% -29.70% -40.60% -67.50% -49.70% -18.70% -49.60% -89.80% 20182019202020212022202320242025
Free cash flow margin (%)
20182019202020212022202320242025
Debt / equity (×)
0.00× 0.16× 0.48× 20182019202020212022202320242025
EPS ($)
-$3.03 -$1.54 -$0.84 -$1.31 -$1.68 20182019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Return on assets-89.8%-49.6%-18.7%-49.7%-67.5%-40.6%-29.7%-17.1%
Return on equity235.1%-188.5%-36.9%-51.4%-75.8%-44.6%-32.0%38.2%
Debt / equity-0.00×0.48×0.16×0.00×————
Current ratio0.536.058.0930.557.858.1111.9349.82

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.